MORRISVILLE, N.C., November 6, 2023 — Premier Research announced today the addition of Elaina N. Haeuber, M.S. as Senior Vice President, Oncology. Women now lead all therapeutic specialty teams at Premier Research. “We continue to expand and deepen our oncology...
Expertise: Oncology & Hematology 100 results
Oncology & Hematology
Elaina N. Haeuber, M.S.
In the field of oncology, as we got better at understanding the changes that occur in cancers at a molecular level, we have seen a shift towards precision medicine. Biomarkers are central to this change and can be leveraged to...
Oncology & Hematology
Operationalizing Biomarker-Guided Oncology Trials: Planning for Success
Advances in genomic and proteomic technologies have led to the identification of numerous biomarkers with potential clinical utility in oncology, including gene mutations, gene amplifications, gene expression signatures, and altered proteins. To date, more than 1,500 potential oncology biomarkers have...
Oncology & Hematology
Regulatory Considerations for Radiotherapeutics and Radiodiagnostics
Oncology & Hematology
The Multi-Faceted World of Clinical Trial Matching in Precision Oncology Studies
The success of clinical trials is contingent upon finding participants who meet certain criteria, ensuring that the resulting study data are meaningful and relevant to the target patient population. Clinical trial matching is the process of identifying and connecting potential...
Oncology & Hematology
ASH
Oncology & Hematology
Six Dosing and Safety Considerations in the Era of Emerging Therapies
Sponsors of emerging hematologic therapies – including gene transfer and gene editing, adoptive cellular, and antibody-drug conjugates – face a unique set of challenges in conducting early-phase, dose-finding studies. Key considerations for developing early-phase trials that can more accurately define...
Cell therapy clinical trials are complex and successfully operationalizing these studies requires careful consideration of the interplay between the patient journey and vein-to-vein logistics workflow.
Oncology & Hematology
Rare Oncology and the FDA: Taking the Guesswork Out of Expedited Pathways
Rare cancers account for 25-30 percent of all new cancer diagnoses and 25 percent of cancer deaths.1 With their poorly understood natural histories, phenotypic heterogeneity, and diverse clinical manifestations, rare cancers pose challenges to drug development and represent a significant...